Not yet recruitingEarly Phase 1NCT07298590

An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease

Studying IgG4-related disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Changhai Hospital
Principal Investigator
Zhuan Liao
Changhai Hospital
Intervention
CD19/BCMA CAR NK(biological)
Enrollment
18 enrolled
Eligibility
18-70 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07298590 on ClinicalTrials.gov

Other trials for IgG4-related disease

Additional recruiting or active studies for the same condition.

See all trials for IgG4-related disease

← Back to all trials